

Ethics Review Committee of Peking University People's Hospital Ethics Review Approval

Approval Number	2026PHB630-001		
Project name	A prospective single-arm cohort study on postoperative self-care in patients undergoing video-assisted ablation of trichilemmal cysts (VAAPS) combined with suture placement (PKUPH-PS01 study)		
Project Source	Self-selected topic		
Research Institution	Peking University People's Hospital	Responsible Department	Stomach enterochirurgia
Principal Investigator	Hu Bozhi	Professional ranks and titles	Not yet evaluated or appointed
Review Category		Review Method	Review Date
Initial Review		Rapid Review	2026/09/07
Re-review following the initial review		Rapid Review	2026/09/22
Review Location	No.11 Xizhimen South Street, Xicheng District, Beijing Ethics Review Committee of Peking University People's Hospital		
Juror	Wang Ling, Gao Zhidong		
Approval Documents	1. Initial application review: 2026/08/21; Post-initial review application: 2026/09/11		
	2. Correction Note		
	3. Research Plan: 1.1, September 8, 2026		
	4. Informed Consent Form: 1.1, September 8, 2026		
	5. Scientific Review Approval Document		
	6. Principal Investigator's Profile		

Review Opinion: Approved

The composition and working procedures of this Ethics Committee comply with international ethical principles, including *the Declaration of Helsinki*, *the International Ethical Guidelines for Biomedical Research Involving Human Subjects*, *the Ethical Review Guidelines for Biomedical Research Involving Human Subjects*, *the Ethical Review Guidelines for Life Science and Medical Research Involving Human Subjects*, *the Good Clinical Practice for Drug Clinical Trials*, *the Ethical Review Guidelines for Drug Clinical Trials*, *the Good Clinical Practice for Medical Device Clinical Trials*, *the Technical Guidelines for Clinical Trials of In Vitro Diagnostic Reagents*, and *the Regulations of the People's Republic of China on the Management of Human Genetic Resources*, as well as relevant domestic regulations and guiding principles of China. Upon review by this Ethics Committee, it is approved to conduct this study in accordance with the approved documents.

Please adhere to the GCP principles and the protocol approved by the ethics committee when conducting clinical trials, and safeguard the health and rights of study participants.

Should any changes be made to the principal investigator, the clinical trial protocol, the informed consent form, recruitment materials, or other related documents during the study, the applicant shall submit an amendment review application.

In the event of a serious adverse event, the applicant shall promptly submit a serious adverse event report.

Applicants shall submit progress reports in accordance with the annual or periodic follow-up review frequency stipulated by the Ethics Committee; should any circumstance arise that could significantly impact the conduct of the trial or increase the risk to study participants, the applicant shall promptly submit a written report to the Ethics Committee.

Applicants are requested to submit a protocol violation report if any of the following circumstances occur: inclusion of study participants who do not meet the inclusion criteria or who meet the exclusion criteria; failure to withdraw study participants despite compliance with trial termination protocols; administration of incorrect treatment or dosage; administration of concomitant medications prohibited by the trial protocol; or any other circumstances that may adversely affect the rights and well-being of study participants, or the scientific validity of the study.

If the applicant suspends or terminates a clinical trial prematurely, please promptly submit a suspension/termination report.

Upon completion of the clinical trial, the applicant shall submit a study completion report.

Annual/Periodic Follow-up Review Frequency	12 months		
Validity period of the approval document	1 year; Deadline: September 22, 2027 (If the trial is not carried out within the specified period, an application for extension of the validity period shall be submitted.)		
Contact Person for the Ethics Review Committee	Cong Cuicui	Contact number	010-88324516
Ethics Review Committee	Ethics Review Committee of Peking University People's Hospital (Seal)		
Signature of the Chairman			
Date	September 23, 2026		

